WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007014029) YIN YANG 1 AS A TREATMENT FOR CARDIAC HYPERTROPHY AND HEART FAILURE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/014029    International Application No.:    PCT/US2006/028356
Publication Date: 01.02.2007 International Filing Date: 21.07.2006
IPC:
A61K 38/18 (2006.01), A61K 45/06 (2006.01), A61K 48/00 (2006.01), A61P 9/04 (2006.01), C12Q 1/00 (2006.01)
Applicants: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE [US/US]; 4001 Discovery Drive, Suite 390C, Sys 588, Boulder, CO 80309 (US) (For All Designated States Except US).
SUCHAROV, Carmen, C. [CA/US]; (US) (For US Only).
BRISTOW, Michael, C. [US/US]; (US) (For US Only)
Inventors: SUCHAROV, Carmen, C.; (US).
BRISTOW, Michael, C.; (US)
Agent: HIGHLANDER, Steven, L.; Fulbright & Jaworski L.L.P., 600 Congress Avenue, Suite 2400, Austin, TX 78701 (US)
Priority Data:
60/7010,600 22.07.2005 US
60/701,768 22.07.2005 US
Title (EN) YIN YANG 1 AS A TREATMENT FOR CARDIAC HYPERTROPHY AND HEART FAILURE
(FR) YIN YANG 1 UTILISE COMME TRAITEMENT POUR UNE HYPERTROPHIE CARDIAQUE ET POUR UNE INSUFFISANCE CARDIAQUE
Abstract: front page image
(EN)The present invention provides for methods of treating and preventing cardiac hypertrophy and heart failure. The present invention provides a link between YYl regulation of fetal gene expression in cardiomyocytes that includes interactions with class II HDACs, ERK1/2 and CaMKII. The present invention further demonstrates that YYl can repress ERKl/2-mediated fetal cardiac gene induction that leads to cardiac hypertrophy.
(FR)L'invention concerne des méthodes pour traiter et pour prévenir une hypertrophie cardiaque et une insuffisance cardiaque. L'invention concerne la régulation de l'expression génique foetale dans des cardiomyocytes et ses interactions avec des HDAC de classe II, ERK1/2 et CaMKII. Dans cette invention, on démontre également que YYl peut contrer une induction génique cardiaque foetale médiée par ERKl/2 qui conduit à une hypertrophie cardiaque.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)